Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
October 2017
-
Media Release
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera®, a first-in-class RadioLigand Therapy (… -
Media Release
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease… -
Media Release
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of… -
Media Release
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time With 54 accepted abstracts, Novartis presence spans from… -
Media Release
Novartis delivered growth on top and bottom line in all divisions in Q3
Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew… -
Media Release
Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions
Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses… -
Media Release
Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen
Der Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +… -
Media Release
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1… -
Story Discovery
Eye on patients, mind on innovation
New Global Head of Ophthalmology Research sees the eye as a frontier of biomedical research.
-
Story From Our Labs
Bringing virtual reality to the lab
Novartis researchers want to use the technology to help them design new drugs.
-
Media Release
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently… -
Featured News
Novartis to host stakeholder dialogue on ways to improve access to healthcare in lower-income countries
The event will take place on November 21 in Basel.